The prognostic value of deep learning-based percentage of tumour-infiltrating lymphocytes in nasopharyngeal carcinoma.

Authors

null

Tianzhu Lu

Jiangxi Cancer Hospital, Nanchang, China

Tianzhu Lu , Fei Xie , Shenghua Zhan , Yujun Hu , Fangyan Zhong , Junjun Chen , Jian-ji Pan , Xiaopeng Xiong , Xiaochang Gong , Shaojun Lin , Qiaojuan Guo , Melvin L.K. Chua , Jingao Li

Organizations

Jiangxi Cancer Hospital, Nanchang, China, Fujian Cancer Hospital, Fuzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China, NHC Key Laboratory of Personalized Diagnosis and Treatment for Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China, Department of Pharmacology, School of Pharmacy, Nanchang University, Nanchang, Jiangxi, China, Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China, Fujian Province Cancer Hospital, Fuzhou, Fujian, China, National Cancer Centre Singapore, Singapore, Singapore

Research Funding

Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences

Background: To calculate the percentage of tumor-infiltrating lymphocytes (TILs) in nasopharyngeal carcinoma (NPC) using deep-learning (DL) algorithms based on digital pathology images and differentiate the outcome. Methods: We recruited 435 patients with primary non-metastatic NPC and 63 patients with de novo metastatic NPC received immunotherapy. TILDL percentage was calculated using the convolutional neural network model, and its ability to differentiate metastasis risk and independent prognostic value were analyzed using Kaplan–Meier survival and multivariate analyses (MVA). Results: The median follow-up time of the training and validation cohorts was 69, and 76 months, respectively. Kaplan–Meier survival analysis showed that the 5-year distant metastasis-free survival (DMFS) and overall survival (OS) of patients with high TILDL were significantly better than those of patients with low infiltration. MVA showed that TILDL degree is an independent prognostic factor for DMFS (training cohort: HR=0.197, 95% CI: 0.077-0.503, p=0.001; validation cohort: HR=0.119, 95% CI: 0.028-0.503, p=0.004) and OS (training cohort: HR=0.418, 95% CI: 0.200-0.873, p=0.020; validation cohort: HR=0.158, 95% CI: 0.048-0.520, p=0.002). The concordance index (C-index) of TILDL was higher than that of the immunohistochemical CD3+, CD8+ T-cell, and CD20+ B-cell densities in terms of the DMFS and OS prediction accuracy. In an immunotherapy cohort of de novo metastatic NPC (n=63), MAV revealed that high TILDL percentage were an independent prognostic factor for PFS (HR=0.368, p= 0.008). Conclusions: TILDL percentage exhibited discriminative capabilities regarding the risk of metastasis and mortality in non-metastatic NPC, and has potential to be a biomarker for dmNPC received immunotherapy. This model will help select patients with a high risk of metastasis and provides a reference for improved individualized treatment.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session B

Track

Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics

Sub Track

Artificial Intelligence/Deep Learning

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 133)

DOI

10.1200/JCO.2024.42.23_suppl.133

Abstract #

133

Poster Bd #

D8

Abstract Disclosures

Similar Abstracts

First Author: Ngar Woon Kam

First Author: Shiaowen David Hsu

First Author: Sapna Pradyuman Patel